Summary
Clinical resistance to chemotherapeutic drugs is an important problem in the treatment of cancer; the circumvention of resistance has become one of the basic goals of cancer therapy. The most frequent form of primary liver cancer is hepatocellular carcinoma, which is essentially refractory to chemotherapy. We earlier showed that TT-232, a new somatostatin analogue developed in our laboratory, exerted a strong antiproliferative effect both in vitro and in vivo, but no growth hormone release inhibitory or antisecretory activity. Here we report that TT-232 has a pronounced antiproliferative effect on differentiated and dedifferentiated, drug-sensitive and multidrug-resistant hepatocellular carcinoma cell lines. TT-232 induces apoptosis at comparable levels in all these hepatoma variants demonstrating that the multidrug resistance of hepatomas does not correlate with a reduced susceptibility to apoptosis induction. These results clearly reveal that the machinery involved in apoptosis is functional in both drug-sensitive and resistant hepatoma variants and can be activated by the somatostatin analogue TT-232.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Arends, M. J. & Wyllie, A. H. (1991). Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol 32: 223–254.
Bonfoco, E., Ceccatelli, S., Manzo, L. & Nicotera, P. (1995). Colchicine induces apoptosis in cerebellar granule cells. Exp Cell Res 218: 189–200.
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J. & Guillemin, R. (1973). Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179: 77–79.
Deschatrette, J. & Weiss, M. C. (1974). Characterization of differentiated and dedifferentiated clones from a rat hepatoma. Biochimie 56: 1603–1611.
Dyson, J. E. D., Simmons, D. M., Daniel, J., McLaughlin, J. M., Quirke, P. & Bird, C. C. (1986). Kinetic and physiological studies of cell death induced by chemotherapeutic agents and hyperthermia. Cell Tissue Kinetics 19: 311–324.
Endicott, J. A. & Ling, V. (1989). The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137–171.
Fardel, O., Lecereur, V. & Guillouzo, A. (1993). Regulation by dexamethasone of P-glycoprotein expression in cultured rat hepatocytes. FEBS Lett 27: 189–193.
Fisher, D. E. (1994). Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539–542.
Fry, D. W., Kraker, A. J., Mcmichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W. & Bridges, A. J. (1994). A specific inhibitor of the epidermal growth factor receptor tyrosin kinase. Science 265: 1093–1095.
Golstein, P. (1997). Controlling cell death. Science 275: 1081–1082.
Gottesman, M. M. (1993). How cancer cells evade chemotherapy. Cancer Res 53: 747–754.
Jaspers, H., Horváth, A., Mezö, I., Kéri, G. & Van Binst, G. (1994). Conformational study of somatostatin analogues with antitumor and/or GH inhibitory activity. Int. J. Pept. Protein Res 43: 271–276.
Kéri, G., Mezö, I., Horváth, A., Vadász, Z., Balogh, A., Idei, M., Vantus, T., Teplán, I., Mak, M., Horváth, J., Pal, K. & Csuka, O. (1993a). Novel somatostatin analogs with tyrosine kinase inhibitory and antitumor activity. Biochem. Biophys. Res. Commun 191: 681–687.
Kéri, G., Mezö, I., Horváth, A., Vadász, Z., Idei, M., Vantus, T., Balogh, A., Bokonyi, G., Bajor, T., Teplán, I., Tamás, J., Mak, M., Horváth, J. & Csuka, O. (1993b). Structure-activity relationship studies of novel somatostatin analogs with antitumor activity. Pept. Res 6: 281–288.
Kéri, G., Échegyi, J., Horváth, A., Mezö, I., Idei, M., Vantus, T., Balogh, A., Vadász, Z., Bokonyi, G. & Ullrich, A. (1996). A tumor selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc Natl Acad Sci USA 93: 12513–12518.
Kéri, G., Échegyi, J., Horváth, A., Idei, M., Teplán, I., Csuka, O., Tejeda, M., Gaál, D., Örfi, L., Szegedi, Z. & Szende, B. (1998). Induction of apoptosis and non-apoptotic programmed cell death by antitumor peptides and peptidomimetics. In Peptides, 1996, Ramage R, Epton R. Mayflower Scientific: UK. 83–86.
Laurent-Crawford, A. G., Krust, B., Muller, S., Riviere, Y., Rey-Fuille, A. M., Bechet, J. M., Montagnier, L. & Hovanessian, A. G. (1991). The cytopathic effect of HIV is associated with apoptosis. Virology 185: 829–839.
Levitzki, A. & Gazit, A. (1995). Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782–1788.
Mehlen, P., Kretz-Remy, C., Preville, X. & Arrigo, A. P. (1996). Human hsp27, Drosophila hsp27 and human αβ-crystallin expression-mediated increase in glutathion is essential for the protective role of these proteins against TNF α-induced cell death. EMBO J 15: 2695–2706.
Morimoto, R. I., Tissières, A. & Georgopoulos, C. (1990). The stress response, function of the proteins and perspectives. In Stress Proteins in Biology and Medicine, Morimoto RI, Georgopoulos C Cold Spring Harbor Academy Press: Cold Spring Harbor 1–36.
Mosser, D. D. & Martin, L. H. (1992). Thermotolerance to apoptosis in a human T lymphocyte cell line. J Cell Physiol 151: 561–570.
Muller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H. & Galle, P. R. (1997). Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99: 403–413.
Ozturk, M. (1996). Molecular biology of liver cancer. In Encyclopedia of Molecular Biology and Molecular Medicine, Vol. 3. Meyers AR VCH: New York 480–491.
Patel, Y. C., Greenwood, M. T., Panetta, R., Demchyshyn, L., Niznik, H. B. & Srikant, C. B. (1995). The somatostatin receptor family. Life Sci 57: 1249–1265.
Pirity, M., Nguyen, V. T., Dubois, M. F., Bensaude, O., Hevér-Szabó, A. & Venetianer, A. (1992). Decreased stress inducibility of the HSP68 protein in a rat hepatoma variant clone. Eur J Biochem 210: 793–800.
Pirity, M. & Hevér-Szabó, A., Venetianer (1996). Overexpression of P-glycoprotein in heart- and/or drug-resistant hepatoma variants. Cytotechnology 19: 207–214.
Roehm, N. W., Rodgers, G. H., Hatfield, S. M. & Glasebrook, A. L. (1991). An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immun Methods 142: 257–265.
Schally, A. V. (1988). Oncological applications of somatostatin analogues. Cancer Res 48: 6977–6985.
Scudiero, D. A., Shoemaker, R. H., Paull, K. D., Monks, A., Tierney, S., Nofziger, T. H., Currents, M. J., Seniff, D. & Boyd, M. R. (1988). Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity using human and tumor cell lines. Cancer Res 48: 4827–4833.
Sen, S. & D’Incalci, M. (1992). Biochemical events and relevance to cancer chemotherapy. FEBS Lett 307: 122–127.
Venetianer, A., Bajnóczky, K., Gál, A. & Thompson, E. B. (1978). Isolation and characterization of L-cell variants with altered sensitivity to glucocorticoid. Somatic Cell Genet 4: 513–530.
Venetianer, A., Pintér, Z. & Gál, A. (1980). Examination of glucocorticoid sensitivity and receptor content of hepatoma cell lines. Cytogenet Cell Genet 28: 280–283.
Venetianer, A. & Bösze, Z. (1983). Expression of differentiated functions in dexamethasone-resistant hepatoma cells. Differentiation 2: 270–278.
Venetianer, A., Pirity, M. & Hevér-Szabó, A. (1994). The function of heat-shock proteins in stress tolerance. Cell Biol Int 18: 605–615.
Wyllie, A. H., Kerr, J. K. & Currie, A. R. (1980). Cell death: the significance of apoptosis. Int Rev Cytol 68: 251–306.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Diaconu, CC., Szathmári, M., Kéri, G. et al. Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232. Br J Cancer 80, 1197–1203 (1999). https://doi.org/10.1038/sj.bjc.6690486
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690486
Keywords
This article is cited by
-
TT-232: An Anti-tumour and Anti-inflammatory Peptide Therapeutic in Clinical Development
International Journal of Peptide Research and Therapeutics (2005)